ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Identifying Patients with Rapid Progression to Diabetic Retinopathy in Type 2 Diabetes: A Simple Prediction Model for Community Settings.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) progression in community-based type 2 diabetes (T2D) remains challenging to predict. This multi-site cohort study aimed to identify novel metabolic risk factors beyond glucose control and develop a resource-adaptable model for prioritizing DR risk screening. Methods: A prospective, multi-site study was conducted among patients with T2D from 2021 to 2023 across 14 community health centers in Northwestern China (Shaanxi). Baseline and follow-up data on demographic, medical history, and laboratory data were collected. DR was assessed by trained retinal specialists through fundus photography and slit-lamp bio-microscopy. LASSO-penalized logistic regression with 10-fold cross-validation was first performed to identify candidate predictors, followed by multivariable logistic regression to construct the prediction model. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis and bootstrap internal validation. Clinical characteristics before and after onset of DR were analyzed using the paired-sample Wilcoxon test. Results: Among 363 participants who completed follow-up, 50 (13.77%) patients developed DR. Patients who developed DR had longer duration of diabetes, higher HbA1c levels, poorer glycemic control, and elevated urine pH. Multivariate logistic regression identified HbA1c (OR = 1.30), urine pH (OR = 2.55), and diabetes duration (OR = 1.06) as independent risk factors. The prediction model showed moderate discrimination, with an apparent AUC of 0.72 and an optimism-corrected AUC of 0.693 after bootstrap internal validation. In paired analyses, patients exhibited significantly higher BUN and eGFR levels and lower serum creatinine after DR onset (all P < 0.05). Conclusions: In this community-based cohort, a prediction model incorporating urine pH, HbA1c, and diabetes duration showed potential for identifying individuals at high risk of incident DR. Urine pH may serve as a simple and accessible metabolic marker for risk stratification, while renal functional alterations may reflect early systemic changes beyond glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.